Exposure of human populations to a wide variety of chemicals has generated concern about the potential neurotoxicity of new and existing chemicals. Experimental studies conducted in laboratory animals remain critical to the study of neurotoxicity. An integrative approach using pharmacokinetic, neuropathological, neurochemical, electrophysiological, and behavioral methods is needed to determine whether a chemical is neurotoxic. There are a number of factors that can affect the outcome of a neurotoxicity study, including the choice of animal species, dose and dosage regimen, route of administration, and the intrinsic sensitivity of the nervous system to the test chemical. The neurotoxicity of a chemical can vary at different stages of brain development and maturity. Evidence of neurotoxicity may be highly subjective and species specific and can be complicated by the presence of systemic disease. The aim of this paper is to give an overview of these and other factors involved in the assessment of the neurotoxic potential for chemicals. This article discusses the neurotoxicity of several neurotoxicants (eg, acrylamide, trimethyltin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, manganese, and ivermectin), thereby highlighting a multidisciplinary approach to the assessment of chemically induced neurotoxicity in animals. These model chemicals produce a broad range of effects that includes peripheral axonopathy, selective neuronal damage within the nervous system, and impaired neuronal-glial metabolism.
INTRODUCTION
Neurotoxicology is the science that involves the study of the adverse structural or functional effects on the nervous system following exposure to chemical agents during development and in maturity. Neurotoxicity may be permanent or reversible, and it can be expressed as neuropathology or as altered neurochemistry, electrophysiology, or behavior (Table 1 ). In general, chemical-induced changes in the structure or persistent changes in behavior, neurochemistry, or neurophysiology of the nervous system are regarded as neurotoxic effects. Reversible effects occurring at doses that could endanger performance in the workplace or that are associated with a known neurotoxicological mechanism of action are also considered adverse. Neurotoxic disorders are one of the leading causes of work-related disease and injury. In addition, the perceived risks (in children and older adults) for learning disabilities and other types of neurologic dysfunction that arise from exposure to environmental contaminants are of serious public concern.
The neurotoxicologist identifies substances that are hazardous to the nervous system and then obtains information on dose-response relationships, interspecies differences in toxic responses, and mechanisms of action. This information is used to assess and manage risks presented by exposure of humans to chemicals. Unfortunately, many neurotoxicants (eg, lead and mercury) were first identified in humans. Thus, a major goal of modern neurotoxicology is to avoid human exposure as the means of detecting whether or not a chemical is neurotoxic. To this end, well-designed experimental studies conducted in laboratory animals are critical to the study of neurotox- icity. The use of animal studies requires an approach that integrates structural and functional endpoints for interpreting adverse changes (Figure 1 ).
FACTORS THAT CONTRIBUTE TO NERVOUS SYSTEM SENSITIVITY
The nervous system is the communication and information-storage system of the body. In addition to coordinating functions that are commonly associated with the brain (eg, learning and memory), virtually all physiological processes are controlled or influenced by the nervous system. The complexity of the nervous system contributes to its vulnerability to toxicant insult. The nervous system is composed of a wide variety of neurons and glial cells. Neurons can be classified on the basis of anatomical location (eg, hippocampal, striatal), primary neurotransmitter (eg, cholinergic, dopaminergic), cellular structure (eg, granule, pyramidal), or function (eg, neuroendocrine, sensory). Three classes of central nervous system (CNS) neuroglia have been identified: astrocytes, oligodendrocytes, and microglia. The Schwann cell is the primary glial cell in the peripheral nervous system. Glial cells are responsible for a broad range of functions, including neuronal support and maintenance, myelin production, and phagocytosis. Preservation of the normal relationship between neurons and glia is critical to maintaining normal nervous system function (1, 38) . Neurotoxicants may disrupt this relationship by selectively or indiscriminately damaging either cell population. An assessment of neuronal and glial integrity is therefore critical to determining whether a chemical is a neurotoxicant.
There are several other features of the nervous system that predispose it to toxic insult. The nervous system has a very high metabolic rate that is almost exclusively dependent on aerobic glucose-dependent metabolism. To support this high metabolic demand, the brain receives approximately 15 % of the total cardiac output and accounts for 20% of the oxygen consumption for the entire body, despite the fact that the brain accounts for only 1.5 to 2% of the total body weight (28) . Thus, the nervous system is extremely sensitive to neurotoxicants that disrupt mitochondrial function and energy metabolism (46) .
High metabolic rate, elevated concentrations of polyunsaturated fatty acids, and low to moderate levels of antioxidant enzymes in the brain also predispose this organ to oxidative damage (22) . The presence of myelin and other lipoproteins contributes to relatively high lipid levels in the nervous system; these high lipid levels make FIGURE Critical elements in characterizing neurotoxicity risk from exposure to a chemical.
the nervous system susceptible to oxidant-induced lipid peroxidation (33) . High brain lipid levels also facilitate the distribution of many classes of low-molecular weight lipophilic chemicals to the nervous system (50) . Once damaged, the nervous system can compensate functionally ; however, its limited potential for repair ultimately restricts this compensatory capability.
THE ROLE OF PATHOLOGY IN NEUROTOXICOLOGY
Neuropathology is frequently used to evaluate the effects of a chemical on nervous system organization and cellular components. Neuropathology frequently identifies vulnerable sites or susceptible cell populations within the nervous system. Neurologic lesions can be classified as neuronopathies (alterations in the neuronal body), axonopathies (changes in the axons), myelinopathies (effects in the myelin sheaths), dendropathies (dendrite effects), and peripheral neuropathies (changes in the peripheral nerves). In general, chemically induced neuroanatomical alterations are regarded as adverse (54) . Thus, careful histologic evaluations form the cornerstone of our knowledge of the toxic neuropathies that alter nervous system structure. Structural changes can often be correlated with altered neurochemistry, behavior, and electrophysiologic function (9) . Many neurotoxicants induce profound functional changes in the absence of any recognizable structural alterations. Thus, reliance solely on neuropathology for the identification of neurotoxicants can be misleading.
The presence of neurologic signs in a toxicant-exposed individual is not always evidence of direct neurotoxicity. For example, in rodents, anorexia and its associated weight loss are accompanied by a wide variety of behavioral changes. Behavioral changes can include delayed pup development, increased motor activity, decreased hind limb grip strength, increased escape behaviors, and cognitive learning deficits (2, 17, 25, 44) . Likewise, chemically induced organ damage may contribute to the development of neurologic signs. For example, portalsystemic encephalopathy is a major neuropsychiatric complication of chronic liver disease. Evidence to date suggests that portal-systemic encephalopathy is the result of ammonia neurotoxicity and of the associated disruption of neuron-astrocytic metabolic interactions and glutamatergic excitatory transmission (11, 23) . These observations indicate that impairment of organ systems other than the nervous system as well as reduced food or water intake can elicit behavioral effects more commonly associated with neurotoxicant exposure. Pathology plays a critical role in determining whether systemic disease occurs following exposure to a putative neurotoxicant.
ACRYLAMIDE, A MODEL PERIPHERAL NEUROTOXICANT
Acrylamide is widely used as a vinyl monomer in the polymer and paper industry. Acrylamide is neurotoxic to experimental animals as well as humans, and recently, acrylamide has been shown to be mutagenic and carcinogenic. Acrylamide has been widely used in neurotoxicology because this chemical reliably induces a progressive peripheral neuropathy. Sensory symptoms are first noted in the hands and feet of acrylamide-exposed humans. With severe exposure, muscle weakness and atrophy occur in the extremities. Associated with these signs is the development of selective peripheral and distal central nerve fiber degeneration in the medulla and the cerebellum (49, 56) .
One reason acrylamide has been widely used as a model neurotoxicant is because it induces similar clinical, neuropathological, and electrophysiological effects in exposed humans and experimental animals. For example, a sensitive test of neurologic function in acrylamide-exposed individuals is an evaluation of touch sensation. The use of this test is based on the experimental observation of the exquisite vulnerability of Pacinian corpuscles and other mechanoreceptors in animals exposed to acrylamide (56) . Both humans and macaques develop reduced sensitivity to touch, which suggests that both experience similar sensory deficits following prolonged acrylamide exposure (12, 27, 42) . Humans and experimental animals exposed to acrylamide develop similar electrophysiological changes. For example, rats given 50 mg acrylamide/ kg body weight a total of 10 times over a 4-week interval develop modest decreases (-~-70°l0 of control values) in tibial nerve-motor nerve conduction velocities (52) .
Workers that have been heavily exposed to a mixture of acrylamide and acrylonitrile also demonstrate reduced motor nerve conduction velocity (12) .
In spite of these similarities, differences do occur among species with respect to acrylamide neurotoxicity. Monkeys and rats exposed to acrylamide develop histopathological evidence of optic tract and P beta retinal ganglion cell degeneration (43, 60) . Monkeys also demonstrate electrophysiological evidence of visual sensory dysfunction, including reduced visual acuity (40) . Surprisingly, similar effects on vision have not been reported to occur in acrylamide-exposed humans.
SELECTIVE VULNERABILITY OF THE CNS
Variable sensitivity of the different parts of the nervous system may occur in response to neurotoxicant exposure. This may result from compartmentalization of biochemical or metabolic functions (eg, regional distributions of neurotransmitters), variable degrees of vascularization and regional blood flows, uptake of a neurotoxicant to a localized brain region, and inherent cellular sensitivities. For example, the oxygen consumption rate of neurons is approximately 10-fold greater than that of glial cells, which may account for the greater sensitivity of neurons to hypoxia-induced damage.
Trimethyltin Neurotoxicity
One compound that demonstrates relative selectivity within the nervous system is trimethyltin (TMT), a chemical used for a variety of industrial and agricultural purposes. TMT neurotoxicity was first reported in humans in 1978 by Fortemps and coworkers (24); 2 chemists were accidentally exposed to TMT while using it to synthesize dimethyltin dichloride. Since that time, sporadic human exposures have occurred. Humans acutely exposed to TMT develop a limbic-cerebellar syndrome characterized by hearing loss, disorientation, amnesia, aggressive behavior, hyperphagia, disturbed sexual behavior, complex partial and tonic-clonic seizures, nystagmus, ataxia, and mild sensory neuropathy (6) . Animals exposed to TMT develop similar signs and will exhibit tremors, hypoactivity followed by hyperactivity, spontaneous seizures, tail mutilation, vocalization, hyperexcitability, and aggression (18) . Histopathological evaluation of TMT-exposed humans and animals demonstrates neuronal degeneration of the granular neurons of the fascia dentate and of the pyramidal cells of the hippocampal Ammon's horn. In animals, this lesion demonstrates species and age sensitivities and may also be influenced by the dosage schedule used (14) . In general, mice are more sensitive to TMT toxicity than are rats. Within the limbic system, mice developed fascia dentate lesions with little involvement of pyramidal cells within Ammon's horn. In contrast, rats develop more extensive lesions within Ammon's horn, and neurons within the fascia dentate are often spared. The sensitivity of pyramidal neurons within the hippocampal Ammon's horn is age dependent and only develops in rats after the pyramidal neurons become functional after postnatal day 7. This observation illustrates the importance of evaluating the effects of chemicals on the nervous system at different stages of brain development and maturity. Although the hippocampus is the primary site of action, TMT also affects other brain regions, including the neocortex, basal ganglia, cerebellum, brain stem, spinal cord, dorsal root ganglia, olfactory cortex, retina, and the inner ear (14) .
TMT is increasingly exploited as a model neurotoxicant in order to study the effects of chemical exposure on rat behavior and hippocampal function (47) . Damage to the hippocampal system (hippocampus, dentate gyrus, and the subicular complex) and to its anatomically linked adjacent cortical areas (entorhinal, perirhinal, and parahippocampal cortices) yields a pattern of memory deficits that resembles that found in human global amnesics. Behavioral data collected from normal monkeys and from monkeys with bilateral medial temporal-lobe lesions demonstrate that the severity of memory impairment depends on the location and extent of damage to the medial temporal lobe (61) . Damage limited to the hippocampal region produces a mild memory impairment, whereas increasing damage to the entorhinal, perirhinal, and parahippocampal cortices results in progressively more severe memory impairment. Results regarding the association between TMT-induced hippocampal damage and memory in exposed rodents are somewhat conflicting. Some investigators report a dose-response relationship between the degree of TMT-induced histopathological damage and impaired memory (3, 19) , whereas others report no such relationship (10) . Thus, it is critical to determine whether TMT (or other chemical treatments) induce nonspecific performance decrement rather than a specific effect on learning or memory (15) .
Manganese Neurotoxicity
Another compound that demonstrates regional selectivity within the nervous system is manganese. The most commonly recognized effect of manganese is an extrapyramidal movement disorder (ie, manganism) that resembles Parkinson's disease (5, 13) . Neurological manifestations of manganism in people include progressive bradykinesia, dystonia, and gait abnormalities. Using modem brain magnetic resonance imaging (MRI) techniques, researchers have demonstrated that patients with manganism develop elevated basal ganglia manganese concentrations (45) . Severely affected patients develop progressive, irreversible loss of dopaminergic neurons in the globus pallidus and nigrostriatal pathway. In humans, manganese-induced lesions are pre-and postsynaptically localized to the dopaminergic nigrostriatal pathway and are associated with the resultant dystonia (5) .
A substantial literature exists regarding significant species differences in the neurotoxicity of manganese. Therefore, extrapolation among manganese-induced effects in rats, nonhuman primates, and humans must be made with caution. The use of MRI has revealed that as with humans, macaques given high doses of manganese develop elevated brain manganese concentrations localized to the striatum, globus pallidus, and substantia nigra (21, 55) . Furthermore, manganese-exposed monkeys have reduced levels of striatal and pallidal dopamine and 3,4-dihydroxyphenylacetic acid and also demonstrate dopaminergic neuronal losses analogous to those seen in manganese-poisoned humans (20, 21, 48) . Monkeys also develop gait and other motor abnormalities that mimic those observed in affected humans. Only a limited number of studies have been conducted that evaluated the effect of manganese on neonatal or adult rat behavior.
None of these studies, however, confirmed development of a behavioral syndrome comparable to that seen in manganese-poisoned humans and monkeys (7) .
The mechanisms involved in the differing response of rodents and primates to manganese are not completely known (4). Regional localization of manganese in humans and monkeys may reflect the role of transferrin in the transport of manganese to the brain. Regions of highest brain manganese accumulation (striatum, globus pallidus, and substantia nigra) are efferent to those brain regions with the highest density of transferrin receptor (29) . In contrast, rats do not demonstrate selective manganese accumulation in the striatum (8) . Another possible explanation for this primate-selective effect is the observation that manganese has a high affinity for neuromelanin and that its deposition is highest in melanin-containing tissues (39) . Neuromelanin levels increase considerably with higher phylogeny, and brain levels are highest in the primate brain regions in which the dopaminergic pathways are most active (41) . Rats, including pigmented strains, have extremely low levels of substantia nigra neuromelanin (34) and thus may not demonstrate the same patterns of manganese accumulation or extrapyramidal symptomatology. THE ROLE OF ASTROCYTES IN 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE-MEDIATED NEUROTOXICITY Very few animal models of Parkinson's disease existed prior to the identification of a Parkinson's-like disease in several illicit drug users; in these drug users, the disease was traced to their intravenous use of a meperidine analog contaminated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (35) . The observation that MPTP exposure in humans and experimental animals induces selective damage of substantia nigra dopaminergic cells has led to its wide spread use as a model neurotoxicant.
Studies with MPTP have demonstrated that astrocytes play a critical role in neuronal injury through their ability to convert innocuous compounds into a toxic metabolite (16) . MPTP is converted to the pyridinium metabolite 1methyl-4-phenylpyridinium (MPP+) by a 2-step reaction that requires the enzyme monoamine oxidase B (MAO-B), which is found in astrocytes and other cells (58) . MPP+ is then sequestered within dopaminergic neurons by the energy-requiring monoaminergic transporters (31) . Inside the neuron, MPP+ is thought to act as a mitochondrial toxin via inhibition of neuronal NADH dehydrogenase activity (26) . Dopaminergic neurons are particularly vulnerable to MPTP toxicity, probably because of their ability to accumulate MPP+ and because of their ability to retain it for a prolonged period of time.
Rats are relatively insensitive to high doses of systemically administered MPTP One possible mechanism for this resistance is the presence of high MAO-B levels in the endothelium of blood vessels in rat brain (51) . Since MPP+ is a polar compound, only a very small amount will cross the blood-brain barrier and accumulate inside the brain. In spite of this, rats will accumulate MPP+ in the nigrostriatal dopaminergic terminals following highdose MPTP exposure (57, 62) . Nevertheless, rats do not develop associated dopaminergic neuronal loss. These results suggest that rats may be inherently insensitive to the neurotoxic effects of MPP+, and this finding may reflect the ability of rat catecholaminergic neurons to survive impaired energy metabolism (57) . THE 
BLOOD-BRAIN BARRIER INFLUENCES IVERMECTIN NEUROTOXICITY
The blood-brain barrier reduces the brain uptake of many drugs, chemicals, peptides, and other solutes from blood. The anatomic basis of the blood-brain barrier is thought to be specialized microvascular endothelial cells. These endothelial cells have decreased capillary-wall permeability because of the presence of complex tight junctions and low endocytic activity. Astrocytes are also implicated in the maintenance, functional regulation, and repair of the blood-brain barrier. For a long time this barrier was considered to be a physical barrier. However, transport of xenobiotics to the brain may also be influenced by the metabolic activity of the blood-brain barrier (30, 32) . P-glycoproteins expressed at the luminal surface of the brain capillary endothelial cells impart additional protection by limiting the nervous system uptake of xenobiotics from the blood (59) . Certain regions of the nervous system (eg, spinal and autonomic ganglia and the circumventricular organs) lack a functional blood-brain barrier. Furthermore, the blood-brain barrier is also incompletely developed at birth, thereby predisposing the infant brain to neurotoxicants that would be normally excluded in adults (53) . Thus, this barrier should only be considered a partial one (rather than a complete one).
Ivermectin is used in veterinary medicine as an anthelmintic and has been used to treat human onchocerciasis. Ivermectin is a CNS gamma-aminobutyric acid agonist, and its primary acute neurological effect is CNS depression in the absence of recognizable neuropathology. In general, ivermectin toxicosis occurs only following extremely high-dose exposure. The relative protection of the nervous system is conferred by P-glycoproteins expressed within brain capillary endothelial cells (36) . Interestingly, a subpopulation of CF-1 mice exists that is relatively sensitive to the neurotoxic effects of ivermectin and other avermectins. Sensitive CF-1 mice are deficient in P-glycoprotein in the intestinal epithelium, brain capillary endothelium, and placenta. These mice develop neurotoxicity following exposure to approximately 2% of the minimum toxic dose of the resistant animal (36, 37) . This observation suggests that even small subpopulations of individuals may be sensitive to the effects of a neurotoxicant. Thus, it is critical that the mechanistic and pharmacokinetic factors that may contribute to neurotoxicity be clearly identified.
CONCLUSIONS
This article provides several examples illustrating the need for a multidisciplinary approach to determine whether a chemical is neurotoxic. This integrated approach relies not only on neuropathology but also considers the effects that a chemical has on behavior and other nervous system functions. In addition, research performed with these model compounds demonstrates the importance of determining the pharmacokinetics and regional brain dosimetry of a neurotoxicant. Ultimately, the toxicity of a compound will be dependent on the concentration of the chemical within the target organ and on the duration of exposure. As illustrated with TMT, manga-nese, and ivermectin, the pharmacokinetic factors that determine chemical disposition must also be identified so that their variation across species and individuals can be measured. In addition, the response of an organism following neurotoxicant exposure can vary dramatically among species. The use of an integrative approach to the study of neurotoxicity is required not only to determine whether a chemical is neurotoxic but also to dramatically improve the risk assessment of these compounds.
